Literature DB >> 18188814

[Epidemiology of chronic hepatitis C in Germany--an analysis of 10,326 patients in hepatitis centres and outpatient units].

D Hüppe1, E Zehnter, S Mauss, K Böker, T Lutz, S Racky, W Schmidt, J Ullrich, I Sbrijer, R Heyne, A Schober, C John, K-H Hey, B Bokemeyer, B Kallinowski, B Möller, S Pape, M Gutmann, U Alshuth, C Niederau.   

Abstract

Little is known about the epidemiology of chronic hepatitis C (CHC) in Germany and especially about the importance of transmission, duration of infection, genotypes, symptoms and quality of life of the patients. The current study prospectively evaluates epidemiological and clinical data of patients infected with the hepatitis C virus (HCV). Using online data entry, various characteristics of 10,326 untreated patients with CHC were documented from March 2003 until May 2006 in 352 centres all over Germany. Mean age of patients was 43.4 years. Patients infected by i.v. drug abuse were considerably younger (36.5 years) than the remaining patients (49.2 years). As indicated by their native language, 64.4% of the patients came from Germany and 19.2% from Russia. 61.7% were infected with genotype 1 and 34.9% with genotype 2 or 3. 45.5% of the patients had been infected by i.v. drug abuse. In at least 5.4% of the patients liver cirrhosis had been proved by biopsy. 63.5% of the patients felt an impairment of quality of life caused by CHC. In many patients infected with hepatitis C socio-economic issues are existent. This is reflected, i.e., in very high rates of unemployment in special subpopulations. Coinfections with hepatitis B and HIV occurred in 1.5% and 4.7%, respectively. Nearly 80% of patients were managed near their homes. The data of the 10 326 patients represent about 2% of all German patients with CHC. This database is up to now the largest of its kind and gives a representative insight into the epidemiological situation of CHC in Germany.

Entities:  

Mesh:

Year:  2008        PMID: 18188814     DOI: 10.1055/s-2007-963691

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  15 in total

1.  Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection.

Authors:  Claudia Roeder; Sabine Jordan; Julian Schulze Zur Wiesch; Heike Pfeiffer-Vornkahl; Dietrich Hueppe; Stefan Mauss; Elmar Zehnter; Sabine Stoll; Ulrich Alshuth; Ansgar W Lohse; Stefan Lueth
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Chronic hepatitis C: treat or wait? Medical decision making in clinical practice.

Authors:  Claus Niederau; Dietrich Hüppe; Elmar Zehnter; Bernd Möller; Renate Heyne; Stefan Christensen; Rainer Pfaff; Arno Theilmeier; Ulrich Alshuth; Stefan Mauss
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

3.  HEPATITIS C VIRUS GENOTYPES IN INJECTING DRUG USERS FROM ROMANIA.

Authors:  Camelia Sultana; Codruta Vagu; Aura Temereanca; Camelia Grancea; Josefina Slobozeanu; Simona Ruta
Journal:  Cent Eur J Med       Date:  2011-10

Review 4.  Hepatitis C virus infection and the brain.

Authors:  Karin Weissenborn; Anita B Tryc; Meike Heeren; Hans Worthmann; Henning Pflugrad; Georg Berding; Martin Bokemeyer; Hans L Tillmann; Annemarie Goldbecker
Journal:  Metab Brain Dis       Date:  2009-01-07       Impact factor: 3.584

Review 5.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

6.  Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.

Authors:  Claus Niederau; Stefan Mauss; Andreas Schober; Albrecht Stoehr; Tim Zimmermann; Michael Waizmann; Gero Moog; Stefan Pape; Bernd Weber; Konrad Isernhagen; Petra Sandow; Bernd Bokemeyer; Ulrich Alshuth; Hermann Steffens; Dietrich Hüppe
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

7.  Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.

Authors:  Jona T Stahmeyer; Siegbert Rossol; Sebastian Liersch; Ines Guerra; Christian Krauth
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

8.  High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients.

Authors:  Johannes Vermehren; Beate Schlosser; Diana Domke; Sandra Elanjimattom; Christian Müller; Gudrun Hintereder; Karin Hensel-Wiegel; Rudolf Tauber; Annemarie Berger; Norbert Haas; Felix Walcher; Martin Möckel; Ralf Lehmann; Stefan Zeuzem; Christoph Sarrazin; Thomas Berg
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

9.  Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.

Authors:  Jona T Stahmeyer; Siegbert Rossol; Florian Bert; Klaus H W Böker; Harald-Robert Bruch; Christoph Eisenbach; Ralph Link; Christine John; Stefan Mauss; Renate Heyne; Eckart Schott; Heike Pfeiffer-Vornkahl; Dietrich Hüppe; Christian Krauth
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations.

Authors:  Barbara Bertisch; Fabio Giudici; Francesco Negro; Darius Moradpour; Beat Müllhaupt; Alberto Moriggia; Janne Estill; Olivia Keiser
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.